About Us

Who we are

Outset Medical is changing dialysis – one of the largest, most expensive, and stagnant areas of healthcare. Headquartered in San Jose, California, Outset operates across the United States and manufactures in North America. Our team is innovative, talented, and growing quickly. Learn about careers at Outset.

What we do

We are focused on creating change, driving widespread adoption of new technology, and delivering on the promise of an improved experience for patients and lower cost of care for healthcare providers.

Why we do it

We are fueled by the opportunity to give people their lives back.

When we succeed, patients will be able to fit dialysis into their life instead of fitting their life around dialysis. They will ultimately determine when, where, and how they dialyze.

Evolution of Outset

How did we get here? A brief timeline of company milestones.

2010

HD+ is officially funded
2013

First human treatments on Tablo^® in Mexico City
2014

FDA clearance for acute and chronic use, and we gain a CE Mark
2015

HD+ becomes Outset Medical
2016

2nd generation of Tablo is initiated; home clinical trial begins
2017

First use of Tablo in the acute setting at Cleveland Clinic
2018

Tablo launches commercially
2019

Home IDE completed; U.S. Dept. of HHS selects Tablo for disaster relief
2020

FDA clearance for home use; Outset goes public, listed on NASDAQ
2021

Tablo receives landmark TPNIES approval from Centers for Medicare & Medicaid Services; releases inaugural ESG report
2022

Outset ranks #33 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™ list
Present Day

New data shows Tablo increases patient and physician likelihood to adopt home hemodialysis

We’re honored to be recognized for our impactful and innovative solutions.

fast-company-best-workplaces-for-innovators-2023

Leadership

Board of Directors

Leslie Trigg

Chair and CEO

Read bio

Leslie has served as our Chief Executive Officer since November 2014 and was elected Chair in 2022. She joined the company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, she served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, including as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. She serves on the board of directors of the Medical Device Manufacturers Association. Leslie holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, UC Berkeley.

D. Keith Grossman

Lead Independent Director

Read bio

Keith has been a leader in the medical technology industry for more than 35 years. He is currently the Chairman of the Board of Nevro Corporation (NVRO) where he was previously President and CEO from 2019 through April 2023. Prior to Nevro, he was named President and CEO of Thoratec Corp. (THOR) for the second time in 2014. He led the company’s return to growth, a 2.5x increase in company value and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value prior to his arrival. From 2007 to 2011, he served as Managing Director for TPG Biotech, the $1.1 billion venture capital arm of the private equity firm Texas Pacific Group (TPG) where he co-led the medical device investment initiatives. Prior to TPG, he served as CEO, President and Director of Thoratec from 1996 to 2006, increasing the company’s market value more than 12x, and leading the company from no revenue to more than $200 million in annual revenues. Prior to Thoratec, he held a number of commercial and general management roles with companies including SulzerMedica and American Hospital Supply Corp. In addition to serving as Executive Chairman of Nevro, he serves as Vice Chairman of Alcon Inc. (ALC), and he is a former member of the Board of Directors of ViewRay, Inc. (VRAY), Intuitive Surgical, Inc. (ISRG), Kyphon, Inc. (KYPH), Zeltiq (which was acquired by Allergan in 2017), and a number of private medical technology companies.

Karen Drexler

Dir., Nominating & Corp. Gov. Committee Chair

Read bio

Karen is a healthcare industry veteran with a focus on chronic disease management, data analytics, and home based care. She has been an active board member for public and private medical device and diagnostics companies for over a decade. She currently sits on the boards of ResMed (NYSE:RSMD), EBR Systems (ASX:EBR), VIDA Diagnostics, and Huma.AI, and formerly served on the board of Tivic Health Systems (NASDAQ:TIVC). Most recently, she was CEO of Sandstone Diagnostics, a life science tools company focused on increased access to high-quality diagnostic testing. Previously, she founded and served as CEO at Amira Medical until its sale to Roche Diabetes Care. She started her career at LifeScan, where she managed a variety of functions and ultimately executed the sale of the company to Johnson & Johnson.

Patrick T. Hackett

Dir., Audit Committee Chair

Read bio

Patrick is a Special Limited Partner of Warburg Pincus (NYSE:WPCA). He joined Warburg Pincus in 1990 and in his 29 years at Warburg Pincus, he has focused on investments in the technology and health care services fields. Prior to joining Warburg Pincus, he was the Vice President of Cove Capital Associates, a private merchant banking partnership, and prior to that a partner with private equity firm, Acadia Partners. He is a Director of Intelligent Medical Objects, a private healthcare software company. In addition, he serves on the Board of Directors at Stamford Health System, a nonprofit community hospital in Connecticut. He graduated from the University of Pennsylvania with a B.A. in chemistry, and holds a B.S. in economics from the Wharton School at the University of Pennsylvania.

Brent D. Lang

Director

Read bio

Brent is Chairman of the Movella Holdings Inc. board, a company specializing in movement digitization, and a member of the Thriveworks board, a private company that provides mental health services. Brent most recently served as Chairman and Chief Executive Officer of Vocera Communications, a global provider of clinical communication and workflow solutions, until its acquisition by Stryker in 2022. Including his role as Chairman and CEO, he spent more than 20 years in various leadership positions at Vocera, including President and Chief Operating Officer and Vice President of Marketing and Business Development. Earlier in his career, he held leadership roles at 3Com Corporation and worked as a strategy consultant for Monitor Company, Inc. Brent holds a B.S. from the University of Michigan and an M.B.A. from the Stanford University Graduate School of Business. He was also a gold medalist member of the 1988 U.S. Olympic swimming team.

Dale Jones

Dir., Compensation Committee Chair

Read bio

Dale has served as Chief Executive Officer of Magna Vista Partners, a global leadership consulting firm, since 2022. He has also served as a Senior Advisor at Diversified Search Group since 2022, and previously served as its CEO for more than eight years. He began his career in banking, before moving into executive search as a managing partner in the Atlanta office of Heidrick & Struggles International in 1999. In 2007, he relocated to Washington, D.C. to lead a philanthropic initiative, endowed by AOL founder Steve Case and his wife, Jean, that was dedicated to providing access to clean water in Africa. Mr. Jones returned to executive search in 2009, rejoining Heidrick & Struggles to serve as Vice Chairman and Partner of the CEO and Board Practice, where he consulted CEOs and corporate boards on human capital issues including recruiting, retention, succession planning, and corporate governance. Mr. Jones currently serves on the boards of directors of Rollins, Inc. (ROL) and Chick-fil-A, Inc. Previously, he served on the boards of directors of Northwestern Mutual, Kohl’s Corporation, and Hughes Supply.

Andrea Saia

Director

Read bio

Andrea is an accomplished global business leader having focused her 40-year career building leading multinational brands in the consumer products and medical technology businesses with Novartis, Unilever, Revlon and Procter & Gamble. She currently serves on the boards of Align Technology (NASDAQ: ALGN) and Livanova plc (NASDAQ: LIVN). She also served on the board of Coca Cola Enterprises. Previously, she was Global Head of Vision Care for Alcon and CEO/President of Cibavision, a Novartis division.

Learn more about opportunities at Outset.

Visit our careers page

About Us

Leadership

Board of Directors

Investor Relations

Evolution of Outset

HD+ is officially funded

First human treatments on Tablo^® in Mexico City

FDA clearance for acute and chronic use, and we gain a CE Mark

HD+ becomes Outset Medical

2nd generation of Tablo is initiated; home clinical trial begins

First use of Tablo in the acute setting at Cleveland Clinic

Tablo launches commercially

Home IDE completed; U.S. Dept. of HHS selects Tablo for disaster relief

FDA clearance for home use; Outset goes public, listed on NASDAQ

Tablo receives landmark TPNIES approval from Centers for Medicare & Medicaid Services; releases inaugural ESG report

Outset ranks #33 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™ list

New data shows Tablo increases patient and physician likelihood to adopt home hemodialysis

We’re honored to be recognized for our impactful and innovative solutions.

Leadership

Leslie Trigg
Chair and CEO

Chair and CEO

Nabeel Ahmed
Chief Financial Officer

Chief Financial Officer

Michael Aragon
Chief Medical Officer

Chief Medical Officer

John Brottem
General Counsel

General Counsel

Marc Nash
SVP, Operations and R&D

SVP, Operations and R&D

Board of Directors

Learn more about opportunities at Outset.

About Us

Evolution of Outset

HD+ is officially funded

First human treatments on Tablo® in Mexico City

FDA clearance for acute and chronic use, and we gain a CE Mark

HD+ becomes Outset Medical

2nd generation of Tablo is initiated; home clinical trial begins

First use of Tablo in the acute setting at Cleveland Clinic

Tablo launches commercially

Home IDE completed; U.S. Dept. of HHS selects Tablo for disaster relief

FDA clearance for home use; Outset goes public, listed on NASDAQ

Tablo receives landmark TPNIES approval from Centers for Medicare & Medicaid Services; releases inaugural ESG report

Outset ranks #33 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™ list

New data shows Tablo increases patient and physician likelihood to adopt home hemodialysis

We’re honored to be recognized for our impactful and innovative solutions.

Leadership

Chair and CEO

Chief Financial Officer

Chief Medical Officer

General Counsel

SVP, Operations and R&D

Board of Directors

Learn more about opportunities at Outset.

First human treatments on Tablo^® in Mexico City